- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel OOS Therapy
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 137
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Goodyear, Arizona + 96 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1057–1080
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- SOF/VEL/VOX, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 416 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 43
- States / cities
- Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
- Conditions
- Eosinophilic Esophagitis
- Interventions
- CC-93538, Placebo
- Drug · Other
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Phoenix, Arizona + 97 more
- Conditions
- Epilepsy
- Interventions
- Brivaracetam
- Drug
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 767 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more
- Conditions
- Type 1 Diabetes, Pregnancy
- Interventions
- Automated Insulin Delivery (AID)
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Stanford, California • Aurora, Colorado • Rochester, Minnesota + 1 more
- Conditions
- Non Hodgkin Lymphoma
- Interventions
- UCD19 CAR T Cells
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Clinician Experience, Clinician Burnout
- Interventions
- Ambient AI for clinician documentation
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Not listed
- Enrollment
- 232 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Solid Tumour
- Interventions
- Capivasertib, Midazolam
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Durham, North Carolina • Cleveland, Ohio + 2 more
- Conditions
- Overactive Bladder
- Interventions
- onabotulinumtoxinA, Normal saline
- Biological · Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 35 more
- Conditions
- Head and Neck Cancer
- Interventions
- Xevinapant, IMRT, Placebo
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more
- Conditions
- Hepatic Steatosis, Polycystic Ovarian Syndrome, Obesity
- Interventions
- Byetta 5Mcg Pen Injection
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 21 Years · Female only
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Arterial Bleed, Pulmonary Arteriovenous Malformation, Embolization, Hemorrhage
- Interventions
- LOBO Vascular Occlusion System
- Device
- Lead sponsor
- Okami Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 6
- States / cities
- Stanford, California • Aurora, Colorado • Sarasota, Florida + 3 more
- Conditions
- Tumors Characterized by Genetic Abnormalities of ALK
- Interventions
- LDK378
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 304 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
- Conditions
- Bipolar Depression
- Interventions
- lurasidone + (lithium or divalproex), Placebo + (lithium or divalproex)
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Anaheim, California • Chino, California + 21 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- fianlimab, cemiplimab, Pemetrexed, Paclitaxel, Carboplatin, Cisplatin, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 29
- States / cities
- Tucson, Arizona • Yuma, Arizona • Cerritos, California + 24 more
- Conditions
- Hematopoietic/Lymphoid Cancer
- Interventions
- Paced respiration as part of PEPRR, PEPRR
- Device · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Dietary
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
- Interventions
- UX007, Placebo
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Miami, Florida • Norcross, Georgia + 1 more
- Conditions
- Alcohol Use Disorder, Alcohol Drinking, Alcohol Use Disorder (AUD)
- Interventions
- ASP8062, Placebo
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Aurora, Colorado • Providence, Rhode Island
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
- Interventions
- Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 10 more
- Conditions
- Cardiovascular Diseases, Statin Adverse Reaction
- Interventions
- Bempedoic acid 180 mg tablet, Matching placebo tablet
- Drug
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 13,970 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 304
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 246 more
- Conditions
- Renal Transplantation
- Interventions
- Enteric-coated Mycophenolate Acid (EC-MPA), Mycophenolate Mofetil (MMF), Placebo MMF, Placebo EC-MPA
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 37
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 28 more
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- Placebo for AZD8965, AZD8965 low dose, AZD8965 medium dose, AZD8965 high dose
- Other · Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 30 more
- Conditions
- Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
- Interventions
- LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 17
- States / cities
- Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more